Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Akari Therapeutics Q3 2026 Results: Net Loss of $4.84M, Loss Narrows

For the nine months ended September 30, 2026, Akari Therapeutics reported a net loss of $24.1 million, significantly higher than the $12.0 million loss in the prior year period, primarily driven by $12.1 million in impairment losses on goodwill and intangible assets. The company maintained a cash balance of $5.7 million and saw its total shareholders' equity decrease from $28.3 million to $17.5 million during the period.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Profit before tax-4.8-7.5
Net income-4.8-6.4
EPS (diluted, $ a share)$-0.00$-0.00

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: AKTX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Akari Therapeutics Plc: key numbers

Share price
$5.70Close, Nov 17
Shares outstanding
186.09BLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Akari Therapeutics Plc

All →
5:22 PM ET 8-K
Financial Results

Akari Therapeutics Financial Results

Akari Therapeutics reported third quarter 2026 financial results and highlighted the initiation of GLP toxicology studies for its lead TROP2-targeted ADC candidate, AKTX-101. The company ended the quarter with $5.7 million in cash and is progressing toward a planned Phase 1 clinical trial in mid-2027, subject to additional financing.

Term
Q3 2026

“We are entering an increasingly important phase in Akari’s evolution, as we translate the differentiated potential of our PH1 payload platform into a defined path toward clinical development. The initiation of GLP toxicology studies represents a critical step toward bringing AKTX-101 into the clinic.”

Abizer Gaslightwala, President and Chief Executive Officer

“The ADC landscape is rapidly evolving, and we believe the next wave of innovation will be driven not simply by new targets, but by novel payloads capable of overcoming the limitations of current treatments. That is precisely the opportunity we are pursuing with the PH1 payload.”

Abizer Gaslightwala, President and Chief Executive Officer
4:46 PM ET 8-K
Stock Plan Amendment

Akari Therapeutics Stock Plan Amendment

Akari Therapeutics held a Special General Meeting where shareholders approved an amendment to the 2023 Equity Incentive Plan. The amendment increases the number of ordinary shares available for issuance by 144 billion shares, equivalent to 1.8 million American Depositary Shares (ADSs).

4:45 PM ET 8-K
Stock Plan Amendment

Akari Therapeutics Stock Plan Amendment

Akari Therapeutics amended its agreement with CEO Abizer Gaslightwala to increase his base salary to $625,000 and his target bonus to 55%. The amendment includes a grant of 174,000 ADS options and restricted stock units, both of which are subject to shareholder approval of an amendment to the company's 2023 Equity Incentive Plan to increase the share pool.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.